SER-155 在成人异基因造血细胞移植受者中的 Phase 1b 试验结果
A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Nature Medicine 发表的一项部分随机、安慰剂对照 Phase 1b 研究显示，在异基因造血细胞移植受者中，口服多菌株活菌生物治疗产品 SER-155 的安全性与安慰剂相似，且血流感染更少。研究包含开放标签队列和随机对照队列，作者认为该疗法值得进一步开展临床研究。
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y
In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and resulted in fewer bloodstream infections, indicating further clinical investigation of this therapeutic is warranted.
来源：Nature Medicine · nature.com